KMKuifen Ma

Kuifen Ma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kuifen Ma has a total of 59 co-authors. Here are the top co-authors by number of shared publications:

  • Wenjing Hou

    Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, China

    4 shared publications
  • Fang Zeng

    Union Hospital, Tongji Medical College, Huazhong University of Science, Wuhan, China

    3 shared publications
  • Pan Chen

    The First Affiliated Hospital, Sun Yat-sen Univeristy, Guangzhou, China

    3 shared publications
  • Qing Qian

    The First People’s Hospital of Changzhou, Changzhou, China

    3 shared publications
  • Bangqin Hu

    The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

    2 shared publications
  • Jianping Wang

    The Second People’s Hospital of Shanxi Province, Taiyuan, China

    2 shared publications

Latest Publications

  • Open Access

    Development and validation of a knowledge, attitude, and practice questionnaire for management of metabolic complications after solid organ transplantation among medical staff

    by Peishan Cai, Zhou Shu, Xuefeng Cai, Xianpeng Zeng, Qiuxiang Xia, Hongling Ouyang, Kuifen Ma, Fang Zeng

  • Open Access

    Early oseltamivir initiation and influenza outcomes in kidney transplant recipients: a multicenter real-world study

    by Yongting Zhou, Liang Yu, Jianping Wang, Wenjing Hou, Bangqin Hu, Pan Chen, Fang Zeng, Yan Zhang, Qing Qian, Kuifen Ma

  • Pharmaformer: A Transformer-Based Pharmacokinetic Prediction System

    by Linjie Shen, Zhao Li, Kuifen Ma, Saiping Jiang, Wenrui Ma

  • Postoperative delirium or side effects of voriconazole: pharmacist’s viewpoint

    by Qiang Xu, Kuifen Ma, Yanlei Sang

    A 78-year-old Han Chinese woman (height 150 cm, weight 55 kg) underwent left knee prosthesis revision and developed an infection during hospitalisation. Subsequently, the patient developed restlessness and hallucinations. A consultation by a psychiatrist diagnosed postoperative delirium, whereas a clinical pharmacist attributed these symptoms to voriconazole-related adverse effects. The patient had an inadequate response to delirium-targeted treatments, and a voriconazole concentration of 5.0 mg/L was measured. Following the pharmacist's recommendation to discontinue the drug, the symptoms resolved within 4 days. The adverse effects were classified as 'possible' according to the Naranjo Adverse Drug Reaction Probability Scale. To our knowledge, this is the first case highlighting the divergent perspectives between specialist physicians and clinical pharmacists during consultations.


  • Open Access

    Low-Dose Sulfamethoxazole-Trimethoprim Could Prevent Pneumocystis jiroveci Pneumonia in Kidney Transplant Recipients: A Retrospective, Observational Study

    by Rongrong Wang, Xiuhua Wu, Xishao Xie, Chunchun Wei, Jianyong Wu, Kuifen Ma

    Objective: Emerging evidence suggests that low doses of sulfamethoxazole-trimethoprim (TMP-SMX) may offer protection against Pneumocystis jiroveci pneumonia (PJP) in kidney transplant recipients. However, cases of PJP following the withdrawal of prophylaxis have been documented. This study aimed to investigate the relationship between the occurrence of PJP and different regimes of low-dose TMP-SMX prophylaxis. Methods: This retrospective observational study was conducted in the First Affiliated Hospital of Zhejiang University in China. Recipients diagnosed with PJP were included, and four controls were matched for each case based on transplantation time, age, and sex. Multivariate conditional logistic regression was employed to compare the odds of PJP occurrence among different TMP-SMX regimens. Results: From January 1, 2017, to December 31, 2020, 1763 patients underwent kidney transplantation at our center. Thirty-one patients developed PJP post-transplantation, and 124 patients without PJP were included as controls. One patient developed PJP during the prophylaxis period, and the others occurred after TMP-SMX discontinuation, resulting in a PJP incidence rate of 1.36% over the follow-up period. Compared to controls, the PJP group received a significantly lower cumulative TMP-SMX dose (median: 57 single-strength dose [SSD] tablets vs 100 tablets; p = 0.001) and had a shorter prophylaxis duration (median: 6.00 months vs 10.00 months; p = 0.004). They also exhibited higher CMV infection rates (29.0% vs 4.8%, p < 0.001), elevated serum creatinine levels at discharge (174.80μmol/L vs 134.58 μmol/L, p = 0.018), and reduced CD 4+ cell counts (354.12/L vs 542.58/L, p = 0.05). Multivariate analysis revealed that a higher cumulative TMP-SMX dose was significantly associated with a lower risk of PJP (p = 0.005). Subgroup analysis indicated that at least 6 months of TMP-SMX prophylaxis is necessary for PJP prevention in recipients on quarter-strength daily (SMX/TMP 100/20 mg, p = 0.022) or half-single strength daily (SMX/TMP 200/40 to 400/80 mg, p = 0.005) regimens. Conclusion: An adequate prophylactic duration of either quarter-strength daily TMP-SMX or half-single strength daily TMP-SMX may protect kidney transplant recipients from PJP.


  • Open Access

    Clinical efficacy of baloxavir marboxil versus oseltamivir in kidney transplant recipients with influenza

    by Jiali Jiang, Jianping Wang, Wenjing Hou, Bangqin Hu, Pan Chen, Fang Zeng, Yan Zhang, Qing Qian, Kuifen Ma

    Kidney transplant recipients (KTRs) are at high risk for severe influenza and its complications. The effectiveness of baloxavir marboxil (hereafter baloxavir) in infected KTRs is still unknown. In this multicenter retrospective study conducted at eight Grade IIIA hospitals in China, KTRs diagnosed with influenza between October 2023 and March 2024 were enrolled. Of the 246 patients assessed, 117 met the inclusion criteria. There were 59 patients who received baloxavir and 58 patients who received oseltamivir. Patients receiving baloxavir had a longer time from symptom onset to treatment (≤48 h, 59.3% versus 79.3%; P = 0.019). Nevertheless, in comparison with those who were administered oseltamivir, they exhibited no statistically significant difference in time to alleviation of influenza symptoms [4 (2–6) versus 5 (3–7); P = 0.054], duration of fever [3 (2–4) versus 3 (2–4); P = 0.347], or viral clearance [6 (40.0%) versus 10 (58.8%); P = 0.479]. However, among patients who received antivirals within 48 h, baloxavir showed a significant correlation with fever resolution when compared with oseltamivir [2 (2, 3) versus 3 (2–4); P = 0.030]. Meanwhile, among patients who received antivirals after 48 h, a remarkable improvement of symptom alleviation in 5 days was observed in the baloxavir-treated group as compared to the oseltamivir-treated group [18 (75.0%) versus 2 (16.7%); P = 0.001]. In conclusion, compared to oseltamivir, patients may derive benefits from baloxavir treatment within 48 h, but especially after 48 h from symptom onset. IMPORTANCE: The multicenter cohort study is the first to compare the clinical efficacy of baloxavir with oseltamivir in influenza kidney transplant recipients (KTRs). The results showed that there were fewer influenza symptoms but a longer time for viral shedding in KTRs compared to non-immunosuppressed patients. No significant difference regarding time to alleviation of influenza symptoms and fever resolution between baloxavir and oseltamivir was found, which is consistent with CAPSTONE-1, whereas influenza KTRs who received baloxavir could have a shorter fever duration and symptom alleviation in 5 days compared to the oseltamivir-treated group. Our findings may provide guidance for influenza therapy in KTRs, solid organ transplant recipients, and immunocompromised patients.


  • Open Access

    Assessment of Current Practices for Perioperative Antibiotic Prophylaxis in Kidney Transplantation in China: Results from a Nationwide Survey

    by Wenjing Hou, Jiayu Yang, Kuifen Ma, Xiangduan Liu, Hui Yang, Qing Qian, Pan Chen, Fang Zeng, Rongrong Wang, Guangzhao Wang, et al.

    Background: Current guidelines support routine perioperative antibiotic prophylaxis (PAP) to minimize surgical site infection in kidney transplantation (KT), though data regarding the current practices of PAP is lacking in China. Objective: To survey the routine PAP strategies in KT, and analyze main clinical considerations associated with adjusted antibiotic dosing regimens in different Chinese hospitals. Methods: A nationwide survey was conducted on behalf of the National Alliance of Transplant Pharmacists. An online questionnaire was created via Wen Juan Xing (http://www.wjx.cn) and sent to all pharmacists in the Alliance. Results: Twenty-three pharmacists from different teaching hospitals with Grade IIIA participated in the survey, with a response rate of 46.0%. There were wide differences in routine dosing regimens and clinical considerations. Six strategies were involved in living-donor KT and monotherapy was most often used (80.9%), while combination therapy was most common (69.6%) among the ten strategies in deceased-donor KT. Of fifteen antibiotics submitted in the survey, eight agents were prescribed with different doses and/or frequencies among different hospitals. Only 37.5% and 23.1% of the hospitals would stop PAP within 72 hours in living-donor KT and deceased-donor KT, respectively. Among 28 preset factors, four factors were considered significantly important to decide PAP regimens, and eight factors were considered significantly unimportant (P< 0.05). Conclusion: There was wide variability in routine dosing regimens and clinical considerations in PAP decisions in KT. Further investigations are warranted to obtain high-quality evidence and to make PAP in KT more rational.


  • Open Access

    Clinical Characteristics and Epidemiological Analysis of Pneumocystis Jirovecii Pneumonia Infection in Kidney Transplant Patients with Trimethoprim-Sulfamethoxazole Dose Reduction Prophylaxis Strategy

    by Wenya Shan, Liangping Wang, Jiayi Qin, Wenhan Peng, Kuifen Ma

    Background: The administration of trimethoprim-sulfamethoxazole (TMP-SMX) for the prophylaxis of Pneumocystis jirovecii pneumonia (PJP) has proven to be highly efficacious in individuals who have undergone kidney transplantation. Nevertheless, the potential for severe adverse reactions associated with this treatment cannot be overlooked, and the determination of an optimal dosage regimen continues to be a matter of investigation. The current study evaluated the effectiveness of low-dose TMP-SMX for PJP prophylaxis in kidney transplant patients and conducted an analysis of the clinical characteristics and epidemiological trends in patients with PJP infection. Methods: This retrospective analysis studied electronic medical records of 1763 kidney transplant recipients from 2017 to 2020. These patients were initially prescribed a daily half-strength TMP-SMX (40 mg/200 mg), and the efficacy of this regimen was assessed during a follow-up period of 3– 51 months. Results: Under our PJP prevention and adjustment strategy, 24 patients were infected with PJP. The overall morbidity of PJP infection in our study was 1.36%, corroborates with findings from previously published studies. Among these 24 patients, up to 87.5% had their dosage adjusted due to increased creatinine or other adverse reactions, the most frequent dose was daily quarter-strength TMP-SMX (20 mg/100 mg). TMP-SMX prophylaxis successfully postponed and distributed the onset of PJP, with the mean duration from transplantation to the occurrence of PJP being 13.50± 7.11 months. Conclusion: Daily administration of half-strength TMP-SMX can effectively prevent PJP, and prolonging prophylaxis with this medication may potentially reduce the incidence of infection.


  • Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19

    by Hui Yang, Xin Yu, Wenjing Hou, Xiangduan Liu, Jiaojiao Chen, Ying Zhang, Ying Wang, Ying Zhu, Qing Qian, Kuifen Ma, et al.

    Transplant patients face an elevated risk of coronavirus disease 2019 (COVID-19) morbidity and mortality and commonly encounter renal dysfunction. Nirmatrelvir is primarily excreted through the kidneys. The dosage of nirmatrelvir/ritonavir (NR) needs to be adjusted according to the degree of renal function impairment. Nevertheless, NR is not recommended for patients with severe renal impairment (estimated glomerular filtration rate < 30 mL/min) due to a dearth of associated research. In this study, we focus on kidney transplant patients and document and analyze the experiences of using NR in individuals with severe kidney dysfunction. This was a retrospective multicenter study that included transplant recipients hospitalized for COVID-19 in five major tertiary hospitals in China from December 2022 to June 2023. The outcomes consisted of the disease progression rate by day 28, individual disease progression events, safety outcomes, information on adverse events (AEs), and the blood drug concentrations of immunosuppressants. Data were presented with descriptive statistics. All analyses were performed using SPSS version 22. In total, 40 patients were included in the analysis. Considering the potential interaction between drugs, all patients temporarily discontinued their immunosuppressants during the NR treatment. None of the 32 moderate patients experienced disease progression. However, among the eight patients with critical COVID-19, unfortunately, two of them died. During the medication period, four patients experienced a total of six AEs associated with NR. None of them experienced AEs with a maximum grade of ≥3. Blood drug concentrations of immunosuppressants were monitored in 22 of 40 patients, and the blood drug concentrations of immunosuppressants did not show a significant increase, but some patients experienced lower blood drug concentrations. Our findings supported the use of NR therapy for the treatment of COVID-19 in transplant patients with severe renal insufficiency. A modified dose of NR was well-tolerated.


  • Open Access

    Towards the Antiviral Agents and Nanotechnology-Enabled Approaches Against Parvovirus B19

    by Xi Hu, Chen Jia, Jianyong Wu, Jian Zhang, Zhijie Jiang, Kuifen Ma

    Parvovirus B19 (B19V) as a human pathogenic virus, would cause a wide range of clinical manifestations. Besides the supportive and symptomatic treatments, the only FDA-approved antiviral drug for the treatment of B19V is intravenous immunoglobulins, which however, have limited efficacy and high cost. By far, there are still no virus-specific therapeutics clinically available to treat B19V infection. Therefore, exploiting the potential targets with a deep understanding of the life cycle of B19V, are pivotal to the development of B19V-tailored effective antiviral approaches. This review will introduce antiviral agents via blocking viral invasion, inhibiting the enzymes or regulatory proteins involved in DNA synthesis, and so on. Moreover, nanotechnology-enabled approaches against B19V will also be outlined and discussed through a multidisciplinary perspective involving virology, nanotechnology, medicine, pharmaceutics, chemistry, materials science, and other fields. Lastly, the prospects of the antiviral agents and nanosystems in terms of fabrication, clinical translation and potential breakthroughs will be briefly discussed.